Toggle Main Menu Toggle Search

Open Access padlockePrints

The effects of parathyroid hormone peptides on the peripheral skeleton of postmenopausal women. A systematic review

Lookup NU author(s): Dr Terry AsprayORCiD


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


© 2017 Elsevier Inc. Given current developments in anabolic therapy for bone, we wished to document the effects of the only currently available anabolic therapy, parathyroid hormone (PTH) peptides, on the peripheral skeleton of postmenopausal women. We undertook a systematic review of English articles using MEDLINE, Scopus and the Cochrane Controlled Trials Register (final update 28th March 2016). Additional studies were identified through searches of bibliographies. Studies included those comparing PTH peptides with placebo, with anti-osteoporotic treatments and in combination therapies. Participants had to be postmenopausal women and outcomes included areal or volumetric bone mineral density (BMD) and measurements of bone microarchitecture at peripheral sites, such as the forearm and tibia. Data were extracted independently and reviewed by EVM and LMM. Data on study design were also collected for methodological risk of bias assessment. The heterogeneity between studies, regarding the drug dose and duration, and the site measured, prevented grouped meta-analysis. There were no significant differences in areal BMD between PTH peptides and placebo at peripheral skeletal sites at 12 months. A decrease in aBMD occurred with PTH(1–34) (larger dose) and PTH(1–84) treatment at 18 months follow-up in comparison to the placebo arms. Anti-resorptives seemed to attenuate losses of aBMD at peripheral sites when compared to PTH peptides monotherapy, likely mediated by lower cortical porosity. Finally, PTH peptides combined with bisphosphonates or denosumab attenuated peripheral BMD losses in comparison to PTH peptide monotherapy, with evidence of increased BMD at ultradistal peripheral sites when PTH(1–34) was combined with denosumab or hormone replacement therapy. This summary should act as a reference point for the comparison of new anabolic therapies, specifically in comparison to PTH(1–34).

Publication metadata

Author(s): Metcalf LM, Aspray TJ, McCloskey EV

Publication type: Review

Publication status: Published

Journal: Bone

Year: 2017

Volume: 99

Pages: 39-46

Print publication date: 01/06/2017

Online publication date: 09/03/2017

Acceptance date: 08/03/2017

ISSN (print): 8756-3282

Publisher: Elsevier Inc.


DOI: 10.1016/j.bone.2017.03.007